Tongling Jieya Biologic Technology Co., Ltd. (SHE:301108)
China · Delayed Price · Currency is CNY 47.09
-0.09 (-0.19%)
Oct 28, 2026, 4:00 PM EDT
SHE:301108 Revenue
Tongling Jieya Biologic Technology had revenue of 249.18M CNY in the quarter ending September 30, 2026, a decrease of -2.15%. This brings the company's total for the last twelve months to 875.31M, up 24.29% year-over-year. In the year 2025, Tongling Jieya Biologic Technology had annual revenue of 772.01M with 41.02% growth. That makes Tongling Jieya Biologic Technology the 20,617th largest company in the world by revenue and 3,784th in China.
Revenue (ttm)
875.31M
Revenue Growth
+24.29%
P/S Ratio
6.06
Revenue / Employee
1.38M
Employees
634
Market Cap
5.30B
Revenue by Geography
- Foreign 519.56M 67.3%
- China 252.45M 32.7%
Fiscal year ended Dec 31, 2025 See the full SHE:301108 breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 772.01M | 224.56M | 41.02% |
| Dec 31, 2024 | 547.45M | -75.14M | -12.07% |
| Dec 31, 2023 | 622.59M | -43.98M | -6.60% |
| Jan 1, 2023 | 666.56M | -317.89M | -32.29% |
| Jan 1, 2022 | 984.45M | 241.44M | 32.49% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.